Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

faldaprevir

- PMLiVE

ADA: Empagliflozin overcomes FDA concerns

Boehringer and Lilly expect decision on diabetes treatment by end of 2014

- PMLiVE

EMA: We will allow clinical data download

Regulator says it hasn't watered down trial transparency measures

- PMLiVE

Boehringer gets ‘kite mark’ for health information

First pharma company awarded The Information Standard Certification in UK

- PMLiVE

EMA adaptive licensing project gathers pace

Regulator picks two drugs to pilot early access scheme

- PMLiVE

Pradaxa cleared for new indications in Europe

Boehringer drug set for use in deep vein thrombosis and pulmonary embolism

- PMLiVE

Boehringer aims for nintedanib approval in lung fibrosis by year end

EMA grants accelerated assessment to drug in rare disease

- PMLiVE

Bruno Strigini leaves Merck & Co for Novartis

Will head up an oncology business boosted by the acquisition of GSK's portfolio

- PMLiVE

Boehringer sells injectables business to Hikma for $300m

Bedford Laboratories is part of troubled Ben Venue division

EU flag

EC approves drugs for diabetes and Crohn’s disease

Takeda’s Entyvio and Boehringer/Lilly’s Jardiance get green light

Roche - Basel

CHMP turns down Avastin for brain cancer

Roche set to be denied expanded use for oncology drug in Europe

- PMLiVE

CHMP backs European approval for six new medicines

Recommends drugs by PTC Therapeutics, Roche, Biogen Idec, Octapharma, Alcon and Veloxis Pharma

- PMLiVE

Teva backs laquinimod for MS despite CHMP rejection

EMA confirms negative opinion after re-examination

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links